On Friday, Pfizer announced results of their Phase II/III trial in children 6 months to under 5 years of age. There were two big wins and one massive set back: Wins: Vaccine was safe, so no severe events occurred. The vaccine dosage worked for kids between 6 months and under 2 years.
0 subscriptions will be displayed on your profile (edit)
Skip for now
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.